Key facts
- It has raised $51.1M across 3 recorded rounds; the latest was Seed Round ($4.8M) in Apr 2026.
- General Oncology has filed 12 Form Ds with the SEC since 2015, most recently Apr 2026 ($4.8M sold to 37 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for General Oncology
Funding rounds
3 roundsAbout General Oncology
Developer of a clinical-stage biopharma company designed to manufacture medicines for cancer. The company focuses on developing drugs and methods for the cure of investigational treatment for BRCA-related metastatic pancreatic cancer, enabling patients to avail treatment involving multiple cycles of chemotherapy using melphalan, BCNU, vitamin B12, and vitamin C, along with stem cell transplants to reverse bone marrow suppression.
- Sector
- Healthcare
- HQ
- Brookline, MA, United States
- Founded
- 2015
- Employees
- 8
- Website
- generaloncology.com/
- Ownership
- Privately Held (backing)
General Oncology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in General Oncology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on General Oncology in its N-PORT filings yet. We sweep new filings monthly.